bipolar disorder research program (bdrp) at musc, directed by dr. james (jim) prisciandaro, uses mri and pharmacology to understand and treat bipolar disorder.
bipolar disorder is a chronic mood disorder that causes intense shifts in mood, energy levels and behavior. manic episodes are the main sign of the co
new treatments for bipolar disorder are on the horizon. here’s a look at some of the latest advances, as well as experimental therapies.
many people think that participating in a research study means they will get better treatment for their condition. while this may be true, it’s important to remember that a research … continued
other mental illness diagnoses, taking psychotropic medication (prescribed to treat those illnesses, and specific health service use patterns are strong indicators of bipolar disorder, show researchers from the university of manchester and keele university. the findings – published in the british journal of general practice – will enable do...
global perspectives on bipolar disorder treatment: in-depth comparative analysis of international guidelines for medication selection - volume 10 issue 3
web site created using create-react-app
new research is helping practitioners better understand the symptoms of pediatric bipolar disorder.
introduction bipolar disorder is a chronic and complex disorder that can be difficult to treat. the objective of this retrospective study was to describe treatment patterns among patients with bipolar disorder. methods adults newly diagnosed with bipolar disorder from 2016 to 2018 were identified using the ibm® marketscan® commercial claims database. patients were enrolled for at least 12 months prior to and 6 months after initial diagnosis. lines of therapy (lots) were continuous treatment periods based on filled prescriptions; medications, such as antidepressants, mood stabilizers, atypical antipsychotics, benzodiazepines, stimulants, and off-label prescriptions, were recorded. all data were analyzed descriptively. results a total of 40,345 patients met criteria. the most common initial episode types were bipolar ii (38.1%), and bipolar i depression (29.8%), mania (12.8%), and mixed features (12.0%). among all episode types, approximately 90% of patients received treatment (lot1) and approximately 80% of these patients received at least one additional lot. across all episode types, the most common medication classes in lot1 (n = 36,587) were mood stabilizers (43.8%), antidepressants (42.3%; 12.9% as monotherapy), atypical antipsychotics (31.7%), and benzodiazepines (20.7%); with subsequent lots, antidepressant (51.4–53.8%) and benzodiazepine (26.9–27.4%) usage increased. also in lot1, there were 2067 different regimens. treatment patterns were generally similar across episode type. conclusions antidepressants and benzodiazepines were frequently prescribed to treat bipolar disorder despite guidelines recommending against use as frontline therapy. these results highlight the considerable heterogeneity in care and suggest that many clinicians treating bipolar disorder are not using evidence-based prescribing practices.
a multidisciplinary team of researchers based at yale will launch a series of studies aimed at accelerating understanding of bipolar disorder and generating new
the mood and anxiety disorders treatment and research program at the university of pennsylvania strives to provide the best in cutting-edge treatment for psychiatric illness.
explore innovative treatments for bipolar disorder mood swings and energy shifts. discover new hope for managing this challenging condition.
background when assessing the value of an intervention in bipolar disorder, researchers and clinicians often focus on metrics that quantify improvements to core diagnostic symptoms (e.g., mania). providers often overlook or misunderstand the impact of treatment on life quality and function. we wanted to better characterize the shared experiences and obstacles of bipolar disorder within the united states from the patient’s perspective. methods we recruited 24 individuals diagnosed with bipolar disorder and six caretakers supporting someone with the condition. participants were involved in treatment or support services for bipolar disorder in central texas. as part of this qualitative study, participants discussed their everyday successes and obstacles related to living with bipolar disorder during personalized, open-ended interviews. audio files were transcribed, and nvivo software processed an initial thematic analysis. we then categorized themes into bipolar disorder-related obstacles that limit the patient’s capability (i.e., function), comfort (i.e., relief from suffering) and calm (i.e., life disruption) (liu et al., febclin orthop 475:315–317, 2017; teisberg et al., mayacad med 95:682–685, 2020). we then discuss themes and suggest practical strategies that might improve the value of care for patients and their families. results issues regarding capability included the struggle to maintain identity, disruptions to meaningful employment, relationship loss and the unpredictable nature of bipolar disorder. comfort related themes included the personal perception of diagnosis, social stigma and medication issues. calm themes included managing dismissive doctors, finding the right psychotherapist and navigating financial burdens. conclusions qualitative data from patients with bipolar disorder helps identify gaps in care or practical limitations to treatment. when we listen to these individuals, it is clear that treatments must also address the unmet psychosocial impacts of the condition to improve patient care, capability and calm.
bipolar disorder usually requires a long-term treatment plan often involving a range of treatment options to properly manage the condition.
the dauten family center for bipolar treatment innovation at mass general is dedicated to finding new treatments for bipolar disorder, providing high-quality clinical care and educating our colleagues, our patients, their families and the community about this disorder.
what is new in research on bipolar disorder?
what is new in research on bipolar disorder?
the pandemic increased our collective focus on mental health, driving research into conditions such as bipolar disorder.
bipolar disorder is a mental illness characterized by extreme mood swings, including episodes of mania and depression. these mood swings can affect a person
who fact sheet on bipolar disorder, including key facts, symptoms and patterns, risks and protective factors, treatment and care, and who response.
backgroundbipolar disorder (bd) is predominantly treated with psychotropic drugs, but bd is a complex medical condition and the contribution of psychotropic ...
purpose of review to assess the effectiveness of drug and nondrug therapies for treating acute mania or depression symptoms and preventing relapse in adults with bipolar disorder (bd) diagnoses, including bipolar i disorder (bd-i), bipolar ii disorder (bd-ii), and other types. key messages acute mania treatment: lithium, asenapine, cariprazine, olanzapine, quetiapine, risperidone, and ziprasidone may modestly improve acute mania symptoms in adults with bd-i.
va hsr&d research topics
bipolar disorder is a serious mental health condition that affects more than 40 million people worldwide. while bipolar disorder research has historically been underfunded, three family philanthropies recently announced they are donating $150 million to launch a new initiative known as bd2: breakthr
stem cell clinical trial for treatment-resistant bipolar depression the purpose of this placebo-controlled study is to test the use of one infusion of stem cells in addition to a mood stabilizing medication as a treatment for bipolar disorder. transcranial direct...
dr. andrew nierenberg is an international expert on bipolar disorder and the director of the dauten family center for bipolar treatment innovation at massachusetts general hospital.
new research from the universities of keele and manchester has found that psychiatric diagnoses, psychotropic prescriptions, and health service use patterns are strong indicators of bipolar disorder.
bipolar disorders are common, recurrent mental health conditions of variable severity that are difficult to diagnose. affected individuals have higher rates of other mental health disorders, substance use disorders, and comorbid chronic medical illnesses. new diagnostic criteria and specifiers with attention on mixed features and anxious distress aid the physician in recognizing episode severity and prognosis. physicians should consider bipolar disorder in any patient presenting with depression. pharmacotherapy with mood stabilizers, such as lithium, anticonvulsants, and antipsychotics, is a first-line treatment that should be continued indefinitely because of the risk of patient relapse. active lifestyle approaches include good nutrition, exercise, sleep hygiene, and proper weight management. monotherapy with antidepressants is contraindicated during episodes with mixed features, manic episodes, and in bipolar i disorder. ongoing management involves monitoring for suicidal ideation, substance use disorders, treatment adherence, and recognizing medical complications of pharmacotherapy. psychotherapy is a useful adjunct to pharmacotherapy. patients and their support systems should be educated about the chronic nature of this illness, possible relapse, suicidality, environmental triggers (e.g., seasonal light changes, shift work, other circadian disruption), and the effectiveness of early intervention to reduce complications.
nyu langone mental health specialists offer expert treatment for bipolar disorder. learn more.
bipolar disorders (bds) are recurrent and sometimes chronic disorders of mood that affect around 2% of the world’s population and encompass a spectrum between severe elevated and excitable mood states (mania) to the dysphoria, low energy, and despondency of depressive episodes. the illness commonly starts in young adults and is a leading cause of disability and premature mortality. the clinical manifestations of bipolar disorder can be markedly varied between and within individuals across their lifespan. early diagnosis is challenging and misdiagnoses are frequent, potentially resulting in missed early intervention and increasing the risk of iatrogenic harm. over 15 approved treatments exist for the various phases of bipolar disorder, but outcomes are often suboptimal owing to insufficient efficacy, side effects, or lack of availability. lithium, the first approved treatment for bipolar disorder, continues to be the most effective drug overall, although full remission is only seen in a subset of patients. newer atypical antipsychotics are increasingly being found to be effective in the treatment of bipolar depression; however, their long term tolerability and safety are uncertain. for many with bipolar disorder, combination therapy and adjunctive psychotherapy might be necessary to treat symptoms across different phases of illness. several classes of medications exist for treating bipolar disorder but predicting which medication is likely to be most effective or tolerable is not yet possible. as pathophysiological insights into the causes of bipolar disorders are revealed, a new era of targeted treatments aimed at causal mechanisms, be they pharmacological or psychosocial, will hopefully be developed. for the time being, however, clinical judgment, shared decision making, and empirical follow-up remain essential elements of clinical care. this review provides an overview of the clinical features, diagnostic subtypes, and major treatment modalities available to treat people with bipolar disorder, highlighting recent advances and ongoing therapeutic challenges.
related news large-scale study of brain volume finds genetic links to parkinson’s disease and adhd october 21, 2024 new grant funds study on role of brain’s reward system in autism […]
we generate breakthrough discoveries that advance scientific understanding and lead to new interventions for preventing and treating bipolar disorder.
a study covering the 20 years between 1997 and 2016 shows that substantial changes have occurred in the way doctors are treating outpatients diagnosed with bipolar disorder. among a number of important changes, one in particular stands out: a much smaller fraction of outpatients today are being treated with a mood stabilizer and a greater fraction are being treated with a second-generation antipsychotic medication.
faculty members david bond, md, phd; and piper meyer-kalos, phd, lp; are basing the blueprint on an existing model, hoping to fill current diagnosis/treatment gaps.
learn about nimh research on bipolar disorder. find resources on the signs and symptoms of bipolar disorder, types, and potential treatments and therapies.
this mental health condition causes extreme mood swings that include emotional highs, called mania, and lows, known as depression.
find out about bipolar disorder, including symptoms, how it's diagnosed and treatments.
objective: pharmacological options for treating bipolar disorder have increased over the past 20 years, with several second-generation antipsychotics receiving regulatory approval in the 1990s. the authors describe trends in use of pharmacological agents in the outpatient management of bipolar disorder. methods: using nationally representative data from the 1997–2016 national ambulatory medical care surveys, the authors examined trends in the use of mood stabilizers, first- and second-generation antipsychotics, and antidepressants among psychiatrist visits for which bipolar disorder was listed among the primary diagnoses. a logistic regression model was used to identify statistically significant trends, with covariates including age, gender, race/ethnicity, and primary insurance. results: antipsychotics were increasingly more commonly prescribed, increasing from 12.4% of outpatient visits for bipolar disorder in the 1997–2000 period to 51.4% in the 2013–2016 period (adjusted odds ratio=5.05, 95% ci=3.65–7.01). use of mood stabilizers decreased from 62.3% of visits for bipolar disorder in the 1997–2000 period to 26.4% in the 2013–2016 period (adjusted odds ratio=0.18, 95% ci=0.13–0.27). prescription of antidepressants occurred in 47.0% of visits for bipolar disorder in the 1997–2000 period and 57.5% in the 2013–2016 period. prescription of an antidepressant without a mood stabilizer increased substantially, from 17.9% in the 1997–2000 period to 40.9% in the 2013–2016 period (adjusted odds ratio=2.88, 95% ci=2.06–4.03). conclusions: substantial changes have occurred in the treatment of bipolar disorder over the past 20 years, with second-generation antipsychotics in large measure supplanting traditional mood stabilizers. antidepressant prescriptions persisted despite a lack of evidence for their efficacy in bipolar disorder and concerns about increasing the risk of mania. research is needed to compare the real-world effectiveness and tolerability of newer antipsychotics with those of traditional mood stabilizers.